Top Markets
Coin of the day
Impact Therap-b Impact Therap-b

Impact Therap-b

7630
Pozycja w akcjach #13207
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and... IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
Cena akcji
$1.85
Kapitalizacja rynkowa
$510.85M
Zmiana (1 dzień)
-7.37%
Zmiana (1 rok)
-
Kraj
CN
Handel Impact Therap-b (7630)

Kategoria

Historia stopy dywidendy dla Impact Therap-b (7630)
Stopa dywidendy (TTM) dla Impact Therap-b (symbol akcji: 7630) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Impact Therap-b (7630) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
Firma Stopa dywidendy Kraj
0.57%
US
2.01%
US
2.74%
US
2.69%
CH
2.47%
US